Any manuscript or substantial parts of it submitted to the journal must not be under consideration by any other journal and must be solely the work of the author(s) stated. We run all papers through a plagiarism detection tool on submission. The manuscript should not have already been published in any journal or other citable form.
ecancermedicalscience will ask authors to sign a sole and exclusive licence for all published content. We do not ask authors to transfer ownership of their copyright. We believe this carefully balances the interest of authors and open access principles whilst maintaining the integrity of the journal.
ecancermedicalscience is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE).
Authors associated with the Sunshine Act who need to know specific costs associated with any publishing activities (editing, reprints or translations) should contact Katie Foxall firstname.lastname@example.org.
Receipt of your paper will be acknowledged by email within two working days. This acknowledgment might contain a decision on acceptability.
Reviewers are asked whether the manuscript is scientifically sound and how interesting and innovative it is. The ultimate responsibility for any decision lies with the Editor.
Reviewers are also asked to indicate which articles they consider to be especially significant for clinical application or public health. These articles may be given greater prominence and included in an editorial and/or ecancermedicalscience press release.
Once an article is accepted, html and pdf versions are published within two weeks on ecancer.org. Authors will be able to check the progress of their paper through the submission system at any time by logging in.
ecancermedicalscience publishes using a "pay what you can afford" model. If you have funding to publish your work in an open access journal, you will be charged a £1000 ($1640/EURO 1200) article processing fee. If you do not have access to this funding, you do not have to pay the fee. If you have funding but it is less than this amount, please let us know. Authors of commissioned articles and special issue articles are exempt.
If you are not sure whether you are eligible for funding for open access publication, see SHERPA/JULIET for a list of research funders' open access policies.
Authors will be asked to agree to an exclusive license agreement which states that anyone is free:
Under the following conditions:
Statutory fair use and other rights are in no way affected by the above. Further information concerning our copyright policies can be found here.
For any reuse or distribution, you must make clear to others the licence terms of this work. The best way to do this is with a link to this web page Creative Commons Licence BY 3.0.
Statutory fair use and other rights are in no way affected by the above.
Submission of a manuscript to ecancermedicalscience implies that all authors have read and agreed to its content - and that any experimental research that is reported in the manuscript has been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration.
Any experimental research on animals must follow internationally recognised guidelines. Papers disregarding the welfare of experimental animals will be rejected. A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. Informed consent must also be documented. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within an ethical framework, e.g. if the severity of the experimental procedure is not justified by the value of the knowledge gained.
Authors may find the National Centre for the Replacement Refinement and Reduction of Animals in Research (NC3Rs) latest report “Animal Research: Reporting of In Vivo Experiments” or the United Kingdom's Co-ordinating Committee on Cancer Research (UKCCCR) 'Guidelines for the welfare and use of animals in cancer research' helpful, published in the British Journal of Cancer (2010) 102 1555-1557.
Generic drug names should generally be used. When proprietary brands are used in research, include the brand names in parentheses in the Methods section.
We ask authors of ecancermedicalscience papers to complete a declaration of conflicts of interest, which should be provided as a separate section of the manuscript, to follow the Acknowledgements. Where an author states they have no conflicts of interest, the listing will read 'The author(s) declare that they have no conflicts of interest.'
For all articles that include information or clinical photographs relating to individual patients, written and signed consent from each patient to publish must be collected. The manuscript should also include a statement to this effect in the Acknowledgements section, as follows: "Written consent for publication was obtained from the patient or their relative." This information does not have to be sent with the manuscript however ecancermedicalscience reserves the right to request this information at any time.
ecancermedicalscience recommends, but does not insist, that clinical trials are registered prior to submission in a suitable publicly accessible registry. The trial registers that currently meet all of the International Committee of Medical Journal Editors guidelines can be found at http://www.icmje.org/faq.html.
If appropriate the trial registration number should be included as the last line of the abstract of the manuscript.
A checklist has been developed for randomised controlled trials (CONSORT). Authors are requested to make use of this when drafting their manuscript and peer reviewers will also be asked to refer to this checklist when evaluating randomised controlled trial studies. For authors of systematic reviews, a supplementary file, linked from the Methods section, should reproduce all details concerning the search strategy. For an example of how a search strategy should be presented, see the Cochrane Reviewers' Handbook.
Studies of diagnostic accuracy should be reported according to STARD guidelines.
Authors from pharmaceutical companies, or other commercial organisations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines for pharmaceutical companies, which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to any companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organisations and communications companies.
The involvement of medical writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged, along with their source of funding, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. If medical writers are not listed among the authors, it is important that their role be acknowledged explicitly. Suggested wording: 'We thank xxxx who provided medical writing services on behalf of ABC Pharmaceuticals Ltd.'.
Submission of a manuscript to ecancermedicalscience implies that readily reproducible materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the article.
Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.
Questions regarding the submission process or the online submission system should be addressed to email@example.com